Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Improvements study found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://codyvacdc.ka-blogs.com/90633548/conolidin-to-replace-traditional-painkillers-options